Image Place holder

Mian M. Shahzad, MD, PhD

Specialty: Gynecologic Oncology
Program: Gynecologic Oncology

Call 1-888-MOFFITT

or call 1-888-MOFFITT


Cancer Types Treated: Cervical Cancer, Endometrial (Uterine) Cancer, Ovarian Cancer, Vaginal Cancer

Dr. Shahzad was recruited to Moffitt Cancer Center in 2013 as a gynecologic oncologist in The Center for Women’s Oncology. He completed his Gynecology Oncology fellowship training at the prestigious University of Wisconsin-Madison, School of Medicine and Public Health, alongside with PhD in endocrinology-reproductive physiology with special focus in cancer biology. Early in his career, he has rapidly distinguished himself as a future thought leader in the field. Prior to his clinical fellowship, he earned a Master of Science degree in Cancer Biology and Molecular Carcinogenesis at the University of Texas/MD Anderson Cancer Center and received dedicated basic science research training as a Women's Reproductive Health Research Scholar from Baylor College of Medicine and UT MD Anderson Cancer Center, Houston, Texas.  He has authored and co-authored numerous scientific publications, including peer-reviewed articles, book chapters and invited articles. Dr. Shahzad's clinical interests are in the surgical management of advanced gynecologic malignancies, including cytoreductive surgery for ovarian cancer, complex minimally invasive laparoscopic and robotic surgery for endometrial and cervical cancers as well as fertility sparing surgical techniques.  Dr. Shahzad also sees patients at Moffitt Cancer Center at International Plaza.

Education & Training

Board Certification:

  • Gynecologic Oncology
  • Obstetrics & Gynecology


  • Baylor College of Medicine and UT MD Anderson Cancer Center - Women's Reproductive Health Research Scholar
  • University of Wisconsin Carbone Cancer Center - Gynecologic Oncology


  • State University of New York - Obstetrics and Gynecology

Medical School:

  • Ross University School of Medicine - MD
Participating Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Peglyated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
Intervention: Doxil (doxorubicin liposome); Farletuzumab; Paraplatin (carboplatin); Placebo; Taxol (paclitaxel); carboplatin; doxorubicin liposome; paclitaxel

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology.
Intervention: Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128 + MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
Intervention: MLN0128; MLN1117; TAK-228 (MLN0128); Taxol (paclitaxel); paclitaxel

A Randomized Multicenter Phase II Trial To Evaluate The Safety, Efficacy And Immunogenicity Of Vaccination With Folate Receptor Alpha Peptides Admixed With GM-CSF As A Vaccine Adjuvant Versus GM-CSF Alone In Patients With Platinum Sensitive Ovarian Cancer And A Response Or Stable Disease To Platinum Therapy
Intervention: FR alpha peptide vaccine; GM-CSF; Leukine (GM-CSF); sargramostatin (GM-CSF)

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Intervention: OTL38

A Phase 1b Study of Navicixizumab (OMP-305B83) plus Weekly Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Intervention: Navicixizumab; OMP-305B83 (Navicixizumab); Taxol (paclitaxel); paclitaxel

A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab in BRCA1 and BRCA2 Mutation Carriers with Recurrent Ovarian Cancer
Intervention: CP-675,206 (tremelimumab); Olaparib (Lynparza); tremelimumab

A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer.
Intervention: BMS-936558 (Nivolumab); Cabozantinib (XL 184); Nivolumab; Not Applicable

A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
Intervention: Fluconazole; IL-2 (Interleukin-2); LN-145; MESNA; Neupogen (filgrastim); cyclophosphamide; cytoxan (cyclophosphamide); filgrastim; fludarabine (Fludarabine phosphate)

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Yanai S, Takeuchi S, Nishimura M, Iwasaki K, Johnson MS, Yoshida M, Hakam A, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Kajiwara H, Hasegawa K, Yasuda M, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Pejovic T, Nagano T, Sasaki T, Richmond AM, Post MD, Shahzad MMK, Im DD, Yoshida H, Enomoto T, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. Ann Surg Oncol. 2018 Sep;25(9):2756-2766. Pubmedid: 29971677.
  • Matsuo K, Johnson MS, Im DD, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Klobocista MM, Hasegawa K, Ueda Y, Shida M, Baba T, Satoh S, Yokoyama T, Machida H, Ikeda Y, Adachi S, Miyake TM, Iwasaki K, Yanai S, Takeuchi S, Nishimura M, Nagano T, Takekuma M, Shahzad MMK, Pejovic T, Omatsu K, Kelley JL, Ueland FR, Roman LD. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. J Surg Oncol. 2018 Mar;117(3):488-496. Pubmedid: 29044542.
  • Shahzad MMK, Felder M, Ludwig K, Van Galder HR, Anderson ML, Kim J, Cook ME, Kapur AK, Patankar MS. Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src. PLoS One. 2018 Jan;13(1):e0189524. Pubmedid: 29324748. Pmcid: PMC5764254.
  • Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol. 2018 Feb;117(2):236-244. Pubmedid: 28787528.
  • Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS. Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. Am J Obstet Gynecol. 2018 Apr;218(4):436.e1-436.e7. Pubmedid: 29353030.
  • Kuznicki ML, Robertson SE, Hakam A, Shahzad MM. Metastatic uterine tumor resembling ovarian sex cord tumor: A case report and review of the literature. Gynecol Oncol Rep. 2017 Nov;22:64-68. Pubmedid: 29034309. Pmcid: PMC5633755.
  • Matsuo K, Machida H, Horowitz MP, Shahzad MMK, Guntupalli SR, Roman LD, Wright JD. Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. Am J Obstet Gynecol. 2017 Nov;217(5):580.e1-580.e10. Pubmedid: 28666700.
  • Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham RM. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC Cancer. 2017 Jun;17(1):407. Pubmedid: 28595616. Pmcid: PMC5465458.
  • Matsuo K, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Ueda Y, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Takeuchi S, Nishimura M, Iwasaki K, Yanai S, Klobocista MM, Johnson MS, Machida H, Hasegawa K, Miyake TM, Nagano T, Pejovic T, Shahzad MM, Im DD, Omatsu K, Ueland FR, Kelley JL, Roman LD. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecol Oncol. 2017 Feb;144(2):329-335. Pubmedid: 27931750.
  • Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, Im DD, Bush SH, Ueda Y, Takano T, Blake EA, Hasegawa K, Baba T, Shida M, Satoh S, Yokoyama T, Machida H, Adachi S, Ikeda Y, Iwasaki K, Miyake TM, Yanai S, Nishimura M, Nagano T, Takekuma M, Takeuchi S, Pejovic T, Shahzad MM, Ueland FR, Kelley JL, Roman LD. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017 Apr;145(1):78-87. Pubmedid: 28215838.
  • Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad MM. Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix. Int J Gynecol Cancer. 2016 Mar;26(3):553-560. Pubmedid: 26825841.
  • Ahdallah R, Morse B, Hakam A, Shahzad MM. Pelvic squamous cell carcinoma of unknown primary: a case report and review of the literature. Eur J Gynaecol Oncol. 2016 Jul;37(3):430-433. Pubmedid: 27352581.
  • Matsuo K, Takazawa Y, Ross MS, Elishaev E, Podzielinski I, Yunokawa M, Sheridan TB, Bush SH, Klobocista MM, Blake EA, Takano T, Matsuzaki S, Baba T, Satoh S, Shida M, Nishikawa T, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Fujiwara K, Hazama Y, Kadogami D, Moffitt MN, Takeuchi S, Nishimura M, Iwasaki K, Ushioda N, Johnson MS, Yoshida M, Hakam A, Li SW, Richmond AM, Machida H, Mhawech-Fauceglia P, Ueda Y, Yoshino K, Yamaguchi K, Oishi T, Kajiwara H, Hasegawa K, Yasuda M, Kawana K, Suda K, Miyake TM, Moriya T, Yuba Y, Morgan T, Fukagawa T, Wakatsuki A, Sugiyama T, Pejovic T, Nagano T, Shimoya K, Andoh M, Shiki Y, Enomoto T, Sasaki T, Fujiwara K, Mikami M, Shimada M, Konishi I, Kimura T, Post MD, Shahzad MM, Im DD, Yoshida H, Omatsu K, Ueland FR, Kelley JL, Karabakhtsian RG, Roman LD. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol. 2016 Jul;27(7):1257-1266. Pubmedid: 27052653.
  • Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Zgheib NB, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecol Oncol. 2016 Feb;140(2):259-263. Pubmedid: 26731723. Pmcid: PMC4724442.
  • Al-Niaimi A, Dickson EL, Albertin C, Karnowski J, Niemi C, Spencer R, Shahzad MM, Uppal S, Saha S, Rice L, Nally AM. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma. Gynecol Oncol. 2016 Dec;143(3):521-525. Pubmedid: 27693123.
  • Schickler RL, Abdallah R, McClung EC, Shahzad MM. Primary peritoneal carcinoma presenting as a Sister Mary Joseph's nodule: A case report and review of the literature. Gynecol Oncol Rep. 2016 Aug;17:20-22. Pubmedid: 27354995. Pmcid: PMC4898916.
  • Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan;132(1):166-175. Pubmedid: 24183729. Pmcid: PMC3946949.
  • Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov;3(11):1302-1315. Pubmedid: 24002999. Pmcid: PMC3855315.
  • Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist K, Valentine AD, Palmero LC, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2102-2109. Pubmedid: 24045927. Pmcid: PMC3830519.
  • Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia. 2013 May;15(5):502-510. Pubmedid: 23633922. Pmcid: PMC3638353.
  • Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013 Jan;4:1403. Pubmedid: 23360994. Pmcid: PMC3561638.
  • Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr;330(2):123-129. Pubmedid: 22776561. Pmcid: PMC3498611.
  • Gold AM, Zucker NA, Shahzad MM, Kushner DM. Community screening leading to the diagnosis of androgen insensitivity syndrome at the age of 65. Gynecol Oncol Case Rep. 2012 Nov;3:23-25. Pubmedid: 24371658. Pmcid: PMC3862298.
  • Olawaiye AB, Godoy HE, Shahzad MM, Rauh-Hain JA, Lele SB, Odunsi K. Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer. Eur J Gynaecol Oncol. 2012 Nov;33(5):477-479. Pubmedid: 23185791. Pmcid: PMC5100898.
  • Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb;366(7):610-618. Pubmedid: 22335738. Pmcid: PMC3296780.
  • Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep;71(18):6030-6039. Pubmedid: 21795478. Pmcid: PMC3174342.
  • Matsuo K, Eno ML, Ahn EH, Shahzad MM, Im DD, Rosenshein NB, Sood AK. Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol. 2011 Oct;34(5):488-493. Pubmedid: 20921883. Pmcid: PMC3183315.
  • Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AK. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011 Jun;17(11):3649-3659. Pubmedid: 21531818. Pmcid: PMC3107884.
  • Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun;17(11):3716-3726. Pubmedid: 21512144. Pmcid: PMC3108184.
  • Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 2011 Aug;17(16):5367-5378. Pubmedid: 21737505. Pmcid: PMC4028171.
  • Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr;17(7):1713-1721. Pubmedid: 21300758. Pmcid: PMC3077122.
  • Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011 Apr;13(4):309-319. Pubmedid: 21472135. Pmcid: PMC3071079.
  • Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 Nov;285(46):35462-35470. Pubmedid: 20826776. Pmcid: PMC2975170.
  • Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May;16(9):2562-2570. Pubmedid: 20388851. Pmcid: PMC3955167.
  • Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May;120(5):1515-1523. Pubmedid: 20389021. Pmcid: PMC2860925.
  • Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May;70(9):3687-3696. Pubmedid: 20430760. Pmcid: PMC3202607.
  • Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb;9(3):176-182. Pubmedid: 20009575. Pmcid: PMC3155813.
  • Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug;16(15):3910-3922. Pubmedid: 20538762. Pmcid: PMC2912984.
  • Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug;9(8):2377-2388. Pubmedid: 20682653. Pmcid: PMC2933364.
  • Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug;18(2):185-197. Pubmedid: 20708159. Pmcid: PMC2923653.
  • Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther. 2010 Apr;9(4):985-995. Pubmedid: 20371710. Pmcid: PMC2852465.
  • Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep;101(17):1193-1205. Pubmedid: 19641174. Pmcid: PMC2736292.
  • Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009 Mar;115(5):1021-1027. Pubmedid: 19156916. Pmcid: PMC2649990.
  • Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun;15(11):3770-3780. Pubmedid: 19470734. Pmcid: PMC2752981.
  • Shahzad MM, Lopez-Berestein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resist Updat. 2009 Dec;12(6):148-152. Pubmedid: 19805003. Pmcid: PMC2789192.
  • Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug;8(16):1596-1603. Pubmedid: 19738426. Pmcid: PMC3916970.
  • Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009 Apr;15(8):2695-2702. Pubmedid: 19351748. Pmcid: PMC2746852.
  • Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep;14(17):5437-5446. Pubmedid: 18765535. Pmcid: PMC2766914.

In the News